Phase III Study of Rilvegostomig in Combination With Bevacizumab With or Without Tremelimumab as First-line Treatment of Hepatocellular Carcinoma

This is a Phase III, randomised, open-label, sponsor-blinded, 3-arm, multicentre, global study assessing the efficacy and safety of rilvegostomig in combination with bevacizumab with or without tremelimumab compared to atezolizumab in combination with bevacizumab. This study will be conducted in participants with advanced HCC who are not amenable to curative therapy or locoregional therapy

Trial Details

NCT ID
NCT06921785
Phase
PHASE3
Sponsor
AstraZeneca
Status
RECRUITING
Cancer Type
Hepatocellular Carcinoma (HCC) Liver Cancer
Interventions
  • Tremelimumab
  • Rilvegostomig
  • Bevacizumab
  • Atezolizumab
Locations (sample)
  • Phoenix, Arizona, United States|33.44838,-112.07404
  • Tucson, Arizona, United States|32.22174,-110.92648
  • Palo Alto, California, United States|37.44188,-122.14302
  • Santa Monica, California, United States|34.01949,-118.49138
  • New Haven, Connecticut, United States|41.30815,-72.92816

Key Eligibility Criteria

  • Locally advanced or metastatic and/or unresectable HCC
  • WHO/ECOG performance status of 0 or 1
  • BCLC stage B (that is not eligible for locoregional therapy) or stage C. Child-Pugh Score class A
  • At least one measurable target lesion

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Hepatocellular Carcinoma (HCC) Liver Cancer Trials on Trialify →